Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study

Maurizio Viecca, Dejan Radovanovic, Giovanni Battista Forleo, Pierachille Santus

ARTICLE INFO

Keywords:
Coronavirus
Covid-19
Respiratory failure
Antiplatelet
Coagulation
D-dimer

ABSTRACT

Patients affected by severe coronavirus induced disease-2019 (Covid-19) often experience hypoxemia due to alveolar involvement and endothelial dysfunction, which leads to the formation of micro thrombi in the pulmonary capillary vessels. Both hypoxemia and a prothrombotic diathesis have been associated with more severe disease and increased risk of death. To date, specific indications to treat this condition are lacking.

This was a single center, investigator initiated, compassionate use, proof of concept, case control, phase IIb study (NCT04368377) conducted in the Intermediate Respiratory Care Unit of L. Sacco University Hospital in Milano, Italy. Our objective was to explore the effects of the administration of anti-platelet therapy on arterial oxygenation and clinical outcomes in patients with severe Covid-19 with hypercoagulability.

We enrolled five consecutive patients with laboratory confirmed SARS-CoV-2 infection, severe respiratory failure requiring helmet continuous positive airway pressure (CPAP), bilateral pulmonary infiltrates and a prothrombotic state identified as a D-dimer > 3 times the upper limit of normal. Five patients matched for age, D-dimer value and SOFA score formed the control group.

Beyond standard of care, treated patients received 25 μg/Kg/body weight tirofiban as bolus infusion, followed by a continuous infusion of 0.15 μg/Kg/body weight per minute for 48 hours. Before tirofiban, patients received acetylsalicylic acid 250 mg infusion and oral clopidogrel 300 mg; both were continued at a dose of 75 mg daily for 30 days. Fondaparinux 2.5 mg/day sub-cutaneous was given for the duration of the hospital stay. All controls were receiving prophylactic or therapeutic dose heparin, according to local standard operating procedures.

Treated patients consistently experienced a mean (SD) reduction in A-a O2 gradient of -32.6 mmHg (61.9, P = 0.154), -52.4 mmHg (59.4, P = 0.016) and -151.1 mmHg (56.6, P = 0.011; P = 0.047 vs. controls) at 24, 48 hours and 7 days after treatment. PaO2/FiO2 ratio increased by 52 mmHg (50, P = 0.172), 64 mmHg (47, P = 0.040) and 112 mmHg (51, P = 0.036) after 24, 48 hours and 7 days, respectively. All patients but one were successfully weaned from CPAP after 3 days. This was not true for the control group. No major adverse events were observed.

Antiplatelet therapy might be effective in improving the ventilation/perfusion ratio in Covid-19 patients with severe respiratory failure. The effects might be sustained by the prevention and interference on forming clots in lung capillary vessels and by modulating megakaryocytes’ function and platelet adhesion. Randomized clinical trials are urgently needed to confirm these results.

Abbreviations: A-a O2, alveolar-arterial oxygen gradient; BUN, blood urea nitrogen; Covid-19, coronavirus disease 2019; CPAP, continuous expiratory airway pressure; Hb, hemoglobin; Ht, hematocrit; LDH, lactate dehydrogenase; PT, prothrombin time; PTT, partial thromboplastin time; PaO2, partial pressure of oxygen; PaCO2, partial pressure of carbon dioxide; CRP, C-reactive protein; P/F ratio, partial pressure of oxygen to inspired fraction of oxygen ratio; SaO2, arterial saturation of oxygen; SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; V/Q, ventilation/perfusion; WBC, white blood cells

* Corresponding author at: Department of Biomedical and Clinical Sciences (DIBIC) Division of Respiratory Diseases Università degli Studi di Milano Ospedale L. Sacco, ASST Fatebenefratelli-Sacco Via G.B. Grassi, 74, 20157, Milano, Italy.

E-mail addresses: maurizio.viecca@asst-fsb.sacco.it (M. Viecca), dejan.radovanovic@asst-fsb-sacco.it (D. Radovanovic), giovanni.forleo@asst-fsb-sacco.it (G.B. Forleo), pierachille.santus@unimi.it (P. Santus).

https://doi.org/10.1016/j.phrs.2020.104950

Received 7 May 2020; Received in revised form 18 May 2020; Accepted 19 May 2020
Available online 23 May 2020

1043-6618/ © 2020 Elsevier Ltd. All rights reserved.
1. Introduction

Since December 2019, the disease induced by the severe acute respiratory syndrome coronavirus 2 (COVID-19) has rapidly spread worldwide becoming a pandemic, currently affecting more than three million patients and causing more than 240000 deaths [1]. Critically ill COVID-19 patients experience acute lung failure secondary to parenchymal infiltrates that cause a ventilation/perfusion (V/Q) mismatch and intra-parenchymal shunt [2]. The associated inflammatory reaction leads to a disproportionate endothelial damage and dysfunction, disruption of regulation of perfusion and loss of hypoxic vasoconstriction [2]. The consequent hypercoagulability state repeatedly observed in patients with COVID-19 [3-5] contributes to a fatal deterioration of the V/Q ratio due to micro and macro-thrombosis of the pulmonary vessels [2,3,6].

So far, to avoid this severe complication, thrombotic prophylaxis [7], anticoagulation [8] and thrombolyis [9] have been suggested, but prospective efficacy and safety data are still lacking. Tirofiban is a reversible inhibitor of the glycoprotein (GP) IIb/IIIa receptor that competitively interferes with platelet aggregation mediated by fibrinogen and is currently recommended for the prevention of early myocardial infarction in adult patients presenting acute coronary syndromes without ST elevation [10].

We hypothesized that the administration of tirofiban in patients with severe COVID-19 in association with dual antiplatelet therapy could improve hypoxemia by favoring lung perfusion with a consequent beneficial effect on clinical outcomes and respiratory function.

2. Material and Methods

This was an investigator-initiated, single center, compassionate use, phase Ib, open-label, case control, proof of concept study conducted in the Intermediate Respiratory Care Unit (IRCU) of the Respiratory Disease Unit of L. Sacco University Hospital, Milan, Italy. The study protocol (ClinicalTrials.gov: NCT04368377) was conducted in accordance with the amended Declaration of Helsinki (2013), approved by the local ethical committee (Comitato Etico Milano Area I; 18275/2020) and all patients gave written informed consent.

2.1. Patients

Patients hospitalized in the IRCU were eligible if they were adults with acute de novo severe hypoxemic respiratory failure with a partial arterial pressure of oxygen to fraction of inspired oxygen ratio (PaO2/FIO2) ≤ 250 mmHg requiring helmet continuous positive airway pressure (CPAP), bilateral pulmonary infiltrates, a laboratory confirmed positive nasal swab for SARS-CoV-2 and a D-dimer value 3 times the upper level of normal (for our laboratory the upper level of normal was < 500 mg/dL). Exclusion criteria were: 1) ongoing bleeding or bleeding diathesis, contraindications for anticoagulation or increased bleeding risk or history of bleeding in the last eight weeks; 2) previous stroke or transient ischemic attack or any intracranial pathology in the last six months; 3) need for surgery or major surgery or trauma within the previous six weeks; 4) laboratory confirmed or history of Glucose 6-Phosphate Dehydrogenase (G6PDH) deficiency; 5) confirmed or suspected pregnancy or patients in childbearing age; 6) previous known adverse effects or intolerance to the study molecules; 7) ongoing septic shock; 8) established disseminated intravascular coagulation (DIC) or patients meeting criteria for DIC according to Taylor et al [11]; 9) elevated risk of in hospital fall; 10) Glasgow Coma Scale (GCS) < 15; 11) confirmed diagnosis of dementia or mental disability that could jeopardize the comprehension of the study protocol and the inability to sign the informed consent. Controls were hospitalized patients with Covid-19-related pneumonia and severe respiratory failure that were matched for age, D-dimer value and Sequential Organ Failure Assessment (SOFA) Score [12], and were part of the observational trial ongoing in our Respiratory Unit at the time of the writing (NCT04307459).

2.2. Study design

The compassionate protocol was designed to include five patients. Patients received 25 µg/Kg/body weight tirofiban as bolus i.v. injection (3 minutes, loading dose), followed by a continuous infusion of 0,15 µg/Kg/body weight per minute for 48 hours. Before starting tirofiban, patients were administered acetylsalicylic acid 250 mg i.v. and a loading dose of clopidogrel 300 mg p.o; both compounds were then continued at a dose of 75 mg p.o. daily for 30 days. Concurrent fondaparinux 2.5 mg/day s.c. was given for the duration of the hospital stay. Patients continued the remaining ongoing pharmacological treatment according to the standard of care. Matched controls were administered prophylactic or therapeutic dose of low molecular weight heparin according to local standard operating procedures. The escalation/de-escalation of the respiratory support and of supplemental oxygen was left to the attending physician, with a target peripheral oxygen saturation set at 96%. Vital signs including electrocardiogram tracing, arterial pressure, peripheral oxygen saturation, respiratory rate and heart rate were continuously monitored. Neurological status, signs of active bleeding or the occurrence of adverse effects were monitored throughout the hospital stay.

2.3. Study aim

The aim of the study was to investigate the effect of antplatelet therapy on hypoxemia and the consequent impact on clinical outcomes.

Co-primary exploratory outcomes were the change in PaO2, PaO2/FIO2 ratio and alveolar-arterial oxygen (A-a O2) gradient after 24, 48 and 168 hours (7 days) after first study drug administration.

Secondary exploratory outcomes were: a) degree of intensity of the respiratory support (invasive mechanical ventilation, CPAP, Venturi mask, nasal cannula or room air) 72 and 168 hours (7 days) after study treatment initiation; b) days on CPAP after treatment initiation; c) hemoglobin and platelet count difference from baseline (before treatment) and 24, 48 and 168 hours after study treatment; d) major and minor cardiac and non-cardiac adverse events from study drug initiation until end of hospital stay.

2.4. Clinical and Laboratory measurements

Demographics, body mass index, comorbidities, SOFA score, Acute Physiology and Chronic Health Disease Classification System II (APACHEII) score and GCS were assessed the day of admittance in the IRCU and before starting the study protocol. Arterial blood gas analysis parameters, A-a O2 gradient, PaO2/FIO2 ratio, a complete blood count including the serum dosage of: creatinine, blood urea nitrogen (BUN), c-reactive protein (CRP), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), D-dimer, fibrinogen, bilirubin and lactate dehydrogenase (LDH) were assessed at admission, the same day, 24, 48 and 168 hours (7 days) after initiating the study protocol. A chest X-ray or CT-scan were also collected at admittance following the standard operating procedures of the IRCU. Peripheral oxygen saturation (SpO2), heart rate and respiratory rate were continuously monitored.

Due to the lack of negative pressure ventilation and to the elevated risk of droplet dispersion and consequent ambient contamination, patients with severe respiratory failure were treated with helmet CPAP as previously described [13]. PEEP was regulated by means of an expiratory resistive valve and checked with a handheld manometer, while oxygen flow derived from a dual flowmeter. To titrate PEEP, arterial blood was drawn at low (5 cmH2O) and high (15 cmH2O) PEEP, to estimate lung recruitment. Weaning from the helmet CPAP occurred as suggested by Radovanievic et al [13].
2.5. Study definitions

2.5.1. Laboratory-confirmed SARS-CoV-2 infection

Patients with a nasal swab positive for SARS-CoV-2 infection or positive IgM serum title. A laboratory confirmed diagnosis had to be associated with a clinically confirmed Covid-19 pneumonia, with a history of fever ≥ 3 days and multiple pulmonary infiltrates at the chest X-Ray or chest CT scan.

2.5.2. Acute de novo severe hypoxic respiratory failure

Patients with no history of chronic respiratory failure, with an arterial blood gas analysis performed in room air showing severe hypoxemia with an arterial partial pressure of oxygen (PAO2/FIO2 < 250 mmHg), according to the Berlin definition for Acute Respiratory Distress Syndrome [14]. A-a O2 gradient was computed according to the equation reported in [15].

2.5.3. Septic shock

Septic shock was defined as the concomitant presence of sepsis (life-threatening organ dysfunction caused by a dysregulated host response to infection with a Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score of 2 points or more) and need for vasopressors to maintain a mean arterial pressure of 65 mmHg or greater and a serum lactate level greater than 2 mmol/L (> 18 mg/dL) in the absence of hypovolemia [16].

2.6. Statistical Analysis

Given the compassionate use of the study drug, the exploratory/proof of concept design of the study and the absence of previous literature on the topic, the study was not powered and the sample size was limited to five patients. Data were reported as means and standard deviations after checking for normality by means of the Kolmogorov-Smirnov test. Paired t-test for independent groups was used to compare baseline values between the group of treated patients and the controls. One way Analysis of Variance (ANOVA) and ANOVA for repeated measures were performed to compare the effect of the treatment at different time lags and between groups. A two-tailed, p-value < 0.05 was considered statistically significant. The database was stored on a Microsoft Excel datasheet (Microsoft Corporation, version for Windows 10) and the statistical analyses were performed with IBM SPSS, Statistics for Windows, version 23.0 (Armonk, NY: IBM Corp).

3. Results

3.1. Patients' baseline characteristics

Patients were enrolled between the 9th and 16th April 2020. At baseline, patients had a mean A-a O2 gradient of 248 (70) mmHg indicating V/Q inequality and/or shunting, a PAO2/FIO2 of 146 (42) suggestive of a severe ARDS, and an average D-dimer of 3038 μg/L FEU (995) (Table 1). Baseline demographics, clinical, respiratory and biochemical parameters did not differ in treated patients and matched controls (Table 1).

Patient #1 was a 73 years old men with no comorbidities and a PAO2/FIO2 ratio of 120, that was transferred from a secondary care hospital because of rapidly degenerating respiratory failure (PAO2/FIO2 = 153) and signs of respiratory distress. At admittance, he was put on helmet CPAP with PEEP 7.5 cmH2O and 60% of FiO2 to reach satisfactory peripheral oxygenation.

Patient #2 was a 67 years old active smoker, with a history of rectal cancer successfully treated 6 years before. He was also transferred from the emergency room of a secondary care hospital due to severe respiratory failure (PAO2/FIO2 = 153) and signs of respiratory distress. At admittance, he was put on helmet CPAP with PEEP 7.5 cmH2O and 40% of FiO2. Chest CT scan showed evidence of paraseptal emphysema, numerous subpleural and basilar infiltrates and bilateral ground glass forming a crazy paving pattern. His D-dimer was 3628 μg/L FEU (Table 1 in the Online Supplement).

Patient #3 was a 73 year old woman, with a history of uncontrolled arterial hypertension and type II diabetes. She was moved from a secondary care hospital because of rapidly degenerating respiratory conditions (PAO2/FIO2 of 100) requiring helmet CPAP with 10 cmH2O of PEEP and 60% of FiO2 to reach satisfactory peripheral oxygenation. The chest X-ray showed diffuse interstitial involvement of both lungs and bilateral lower lobe infiltrates. Her D-dimer was 1965 (293) μg/L FEU.

Table 1

|                    | Treated (n = 5) | Matched controls (n = 5) | P    |
|--------------------|----------------|--------------------------|------|
| Males, %           | 80             | 80                       | 1.00 |
| Age, years         | 61.8 (15.4)    | 65.4 (10.7)              | 0.626|
| BMI, Kg/m²         | 28.1 (8.9)     | 30.3 (2.4)               | 0.617|
| Weight, Kg         | 84 (23)        | 77 (5)                   | 0.046|
| SOFA score         | 3.8 (0.8)      | 4.0 (1.2)                | 0.771|
| APACHEII           | 10 (2)         | 10 (2)                   | 0.841|
| GCS, score         | 15 (7)         | 15 (7)                   | 1.000|
| CPAP, days pre     | 9 (6)          | 7 (4)                    | 0.054|
| FiO2, %            | 60 (10)        | 60 (15)                  | 0.763|
| PEP, cmH2O         | 10 (2)         | 10 (2)                   | 0.863|
| Tirofiban load dose, μg/L | 1965 (293) | n/a                      | n/a  |
| Gas exchange       |                |                          |      |
| pH                 | 7.47 (0.5)     | 7.47 (0.4)               | 0.949|
| PaO2, mmHg         | 73.6 (18.6)    | 96.8 (37.1)              | 0.248|
| PaCO2, mmHg        | 38.6 (4.9)     | 39.2 (7.1)               | 0.882|
| PAO2/FIO2, mmHg    | 146 (42)       | 161 (62)                 | 0.664|
| A-a O2, mmHg       | 248 (70)       | 282 (36)                 | 0.362|
| SaO2, %            | 94 (3)         | 96 (4)                   | 0.658|
| HCO3−, mmol/L      | 29.3 (3.0)     | 28.2 (5.2)               | 0.535|
| Lactates, mmol/L   | 1.4 (0.6)      | 1.6 (0.9)                | 0.593|
| Blood count        |                |                          |      |
| WBC, x10⁹/L        | 10616 (3478)   | 10454 (4589)             | 0.951|
| Neutrophils, x10⁹/L| 8500 (5230)    | 9176 (4680)              | 0.797|
| Lymphocytes, x10⁹/L| 1208 (480)     | 730 (208)                | 0.076|
| PLT, x10ⁱ²/L       | 253 (114)      | 251 (125)                | 0.976|
| Hb, g/L            | 11.9 (1.4)     | 12.7 (1.0)               | 0.318|
| Ht, L/L            | 35.2 (4.3)     | 35.6 (4.3)               | 0.887|
| D-dimer, μg/L FEU  | 3038 (995)     | 4038 (1300)              | 0.209|
| fibrinogen, g/L    | 5.6 (1.3)      | 6.2 (0.9)                | 0.432|
| PT, s              | 13.8 (1.3)     | 14.5 (1.4)               | 0.469|
| PTT, s             | 30 (4)         | 33 (5)                   | 0.295|
| LDH, U/L           | 402 (211)      | 591 (291)                | 0.275|
| Creatinine, mg/dL  | 0.68 (0.27)    | 0.83 (0.21)              | 0.345|
| BUN, mg/dL         | 36.4 (7.6)     | 41.2 (13.8)              | 0.515|
| CRP, mg/L          | 62 (45)        | 150 (117)                | 0.157|

Given the compassionate use of the study drug, the exploratory/proof of concept design of the study and the absence of previous literature on the topic, the study was not powered and the sample size was limited to five patients. Data were reported as means and standard deviations after checking for normality by means of the Kolmogorov-Smirnov test. Paired t-test for independent groups was used to compare baseline values between the group of treated patients and the controls. One way Analysis of Variance (ANOVA) and ANOVA for repeated measures were performed to compare the effect of the treatment at different time lags and between groups. A two-tailed, p-value < 0.05 was considered statistically significant. The database was stored on a Microsoft Excel datasheet (Microsoft Corporation, version for Windows 10) and the statistical analyses were performed with IBM SPSS, Statistics for Windows, version 23.0 (Armonk, NY: IBM Corp.).
and requiring a PEEP of 10-12 cmH2O and 40% FiO2. He had undiagnosed obstructive apnea syndrome.

Compression ultrasound of the leg veins was negative in all patients, and, when possible, pulmonary embolism was ruled out. Due to the chronic comorbidities and to the poor availability of ICU beds at the time of the study, patient #2 and #3 received a do not intubate order.

Before entering the study, none of the patients was exposed to chronic treatment with antiplatelet or non-steroidal ant inflammatory drugs.

3.2. Effect on gas exchange

Individual patient data for changes in gas exchange parameters and blood count can be found in tables S1 and S2 of the online Supplement.

All patients consistently experienced a progressive and statistically significant reduction in A-a O2 gradient during the study period (Table 2). After 24, 48 hours and 7 days the A-a O2 was reduced by 33 mmHg (Table 2, Fig. 1 and Table S3). Accordingly, in some patients PaO2 increased and administered FiO2 was reduced (Table S1), justifying the observed increase in PAO2/FIO2 ratio of 52 (70), 64 (48) and 108 (57) (Table 2). After 24, 48 hours and 7 days the A-a O2 was reduced by 33 mmHg (Table 2). A trend was not visible for controls at the same time-points (P = 0.047).

3.3. Effect on coagulation and blood count parameters

Overall, D-dimer tended to decrease in the treated group but not in controls (-1.7 μg/L 6-28 mg/dL after 24 h and 7 days (P = 0.044), and white blood cells, from 10616 to 8570 cells x109/L at 24 h and 7 days (P = 0.242). The latter was paralleled by a normalization of the lymphocytes count (from 1208 to 1422 cells x109/L), that did not occur in the control group (Table 3).

4. Discussion

In this compassionate use, proof of concept study, we observed for the first time a beneficial effect on clinical management and safety.

During the observation period, all patients but one (patient #1) could be weaned from helmet CPAP (Fig. 2). Three patients were put on nasal cannulae and patient #5 was weaned from O2 therapy after 7 days (Fig. 2). Matched controls, after 7 days from starting observation, were still on CPAP (Fig. 2). One patient (CTR5) was intubated. Patient CTR1, CTR2 and CTR5 died during the hospital stay. At 30 days from study enrolment, patients #2, #3 and #4 have been discharged at home in room air conditions with good autonomy in daily life activities. No major nor minor adverse effects have been observed during the follow up at 30 days.

Patient #5 experienced a decrease in hemoglobin after starting the study protocol (Table S2). No signs of active bleeding were detected on a thorax and abdomen CT-scan and his vital signs and neurological status were improving during the hospital stay. He eventually reported a previous history of sideropenic anemia, unknown at the time of the admission. He underwent a single blood transfusion, maintaining thereafter hemoglobin levels > 10 g/L. The patient has been discharged at home in room air conditions and with satisfactory autonomy in his daily life conditions. At 30 days no major nor minor adverse effects have been observed during the follow up.

Patient #1, despite an initial improvement in PaO2, experienced fever, leukocytosis and increased CRP two days after study drug administration (Table 1). Soon after he developed signs of sepsis and respiratory distress and was therefore intubated and transferred to the ICU the 12th of April. This event was not deemed secondary to the study drugs. During the observation period, all patients but one (patient #1) could be weaned from helmet CPAP (Fig. 2). Three patients were put on nasal cannulae and patient #5 was weaned from O2 therapy after 7 days (Fig. 2). Matched controls, after 7 days from starting observation, were still on CPAP (Fig. 2). One patient (CTR5) was intubated. Patient CTR1, CTR2 and CTR5 died during the hospital stay. At 30 days from study enrolment, patients #2, #3 and #4 have been discharged at home in room air conditions with good autonomy in daily life activities. No major nor minor adverse effects have been observed during the follow up at 30 days.

Patient #5 experienced a decrease in hemoglobin after starting the study protocol (Table S2). No signs of active bleeding were detected on a thorax and abdomen CT-scan and his vital signs and neurological status were improving during the hospital stay. He eventually reported a previous history of sideropenic anemia, unknown at the time of the admission. He underwent a single blood transfusion, maintaining thereafter hemoglobin levels > 10 g/L. The patient has been discharged at home in room air conditions and with satisfactory autonomy in his daily life conditions. At 30 days no major nor minor adverse effects have been observed during the follow up.

Patient #1, despite an initial improvement in PaO2, experienced fever, leukocytosis and increased CRP two days after study drug administration (Table 1). Soon after he developed signs of sepsis and respiratory distress and was therefore intubated and transferred to the ICU the 12th of April. This event was not deemed secondary to the study drugs. Patient #1 died the 5th of May 2020, 39 days after hospital admission.

The remaining patients did not experience major or minor adverse events. Two patients underwent echocardiography (patient #1 and patient #5), that excluded indirect signs of pulmonary hypertension.

3.4. Effect on clinical management and safety

During the observation period, all patients but one (patient #1) could be weaned from helmet CPAP (Fig. 2). Three patients were put on nasal cannulae and patient #5 was weaned from O2 therapy after 7 days (Fig. 2). Matched controls, after 7 days from starting observation, were still on CPAP (Fig. 2). One patient (CTR5) was intubated. Patient CTR1, CTR2 and CTR5 died during the hospital stay. At 30 days from study enrolment, patients #2, #3 and #4 have been discharged at home in room air conditions with good autonomy in daily life activities. No major nor minor adverse effects have been observed during the follow up at 30 days.

Patient #5 experienced a decrease in hemoglobin after starting the study protocol (Table S2). No signs of active bleeding were detected on a thorax and abdomen CT-scan and his vital signs and neurological status were improving during the hospital stay. He eventually reported a previous history of sideropenic anemia, unknown at the time of the admission. He underwent a single blood transfusion, maintaining thereafter hemoglobin levels > 10 g/L. The patient has been discharged at home in room air conditions and with satisfactory autonomy in his daily life conditions. At 30 days no major nor minor adverse effects have been observed during the follow up.

Patient #1, despite an initial improvement in PaO2, experienced fever, leukocytosis and increased CRP two days after study drug administration (Table 1). Soon after he developed signs of sepsis and respiratory distress and was therefore intubated and transferred to the ICU the 12th of April. This event was not deemed secondary to the study drugs. Patient #1 died the 5th of May 2020, 39 days after hospital admission.

The remaining patients did not experience major or minor adverse events. Two patients underwent echocardiography (patient #1 and patient #5), that excluded indirect signs of pulmonary hypertension.

3.4. Effect on clinical management and safety

During the observation period, all patients but one (patient #1) could be weaned from helmet CPAP (Fig. 2). Three patients were put on nasal cannulae and patient #5 was weaned from O2 therapy after 7 days (Fig. 2). Matched controls, after 7 days from starting observation, were still on CPAP (Fig. 2). One patient (CTR5) was intubated. Patient CTR1, CTR2 and CTR5 died during the hospital stay. At 30 days from study enrolment, patients #2, #3 and #4 have been discharged at home in room air conditions with good autonomy in daily life activities. No major nor minor adverse effects have been observed during the follow up at 30 days.

Patient #5 experienced a decrease in hemoglobin after starting the study protocol (Table S2). No signs of active bleeding were detected on a thorax and abdomen CT-scan and his vital signs and neurological status were improving during the hospital stay. He eventually reported a previous history of sideropenic anemia, unknown at the time of the admission. He underwent a single blood transfusion, maintaining thereafter hemoglobin levels > 10 g/L. The patient has been discharged at home in room air conditions and with satisfactory autonomy in his daily life conditions. At 30 days no major nor minor adverse effects have been observed during the follow up.

Patient #1, despite an initial improvement in PaO2, experienced fever, leukocytosis and increased CRP two days after study drug administration (Table 1). Soon after he developed signs of sepsis and respiratory distress and was therefore intubated and transferred to the ICU the 12th of April. This event was not deemed secondary to the study drugs. Patient #1 died the 5th of May 2020, 39 days after hospital admission.

The remaining patients did not experience major or minor adverse events. Two patients underwent echocardiography (patient #1 and patient #5), that excluded indirect signs of pulmonary hypertension.
the first time that concomitant treatment with tirofiban, acetylsalicylic acid, clopidogrel and fondaparinux at a prophylactic dose could improve gas exchange efficiency increasing arterial oxygenation and A-a O2 difference in severe patients affected by Covid-19 with a thrombophilic profile. The patients enrolled in the present study had a median D-dimer of 3.375 μg/L, and a median SOFA score of 4, posing them at elevated risk of in-hospital death [17]. Despite patients’ baseline severity, the improvement in peripheral oxygen was consistently paralleled by a reduction in the respiratory assistance without major adverse events, supporting that this treatment might be tested also in ICU patients.

Thrombophilia has been repeatedly reported in ICU patients with Covid-19 [3,4,18], often associated with dramatic increases in D-dimer and fibrinogen values [3]. Recent evidence further demonstrated that both D-dimer values > 1.000 μg/L and higher SOFA scores were associated with increased odds of death in hospitalized patients with Covid-19 [17]. Although sometimes DIC features have been observed in patients with severe Covid-19 [11], low platelets counts and bleeding were rarely reported [3,7,19], suggesting that hypercoagulability is fostered by the severe inflammatory state [3]. Electron microscopy and immunohistochemistry analyses have recently provided evidence of an elevated number of megakaryocytes and platelet-fibrin thrombi in alveolar capillaries from lung tissue of deceased patients with severe Covid-19 [6]. Megakaryocytes are hematopoietic cells specialized in the production of platelets that migrate from the bone marrow to the lung microvasculature [20], where they release platelets that are retained and sheared in the pulmonary capillary vessels [20,21]. We hypothesize that the administration of the GP IIb/IIIa inhibitor tirofiban might have prevented the formation of newly assembling clots promoted by the dysfunctional endothelium of lung capillaries. In fact, both hypoxia and sepsis can independently promote platelet aggregation [22], mediated by the release of Von Willebrand factor, which was found greatly increased in the whole blood of ICU patients with Covid-19 [3]. The latter effect, associated with the inhibition of cyclo-oxygenase (COX) present in platelets and megakaryocytes and promoted by acetylsalicylic acid and the clopidogrel-related modulation of the ADP megakaryocytes receptor [23], might have impeded the consolidation of forming thrombi, thus improving regional ventilation/perfusion mismatch and explaining the rapid increase in PaO2 and the reduction in A-a O2 gradient [24]. Moreover, it may be conceivable to suppose that the consequent reduction in the alveolar-endothelial thickness might have led to a local improvement in oxygen diffusion capacity [25] thus in part justifying the increase in arterial PaO2.

Platelet derived thromboxane A2 (TxA2) has vasoreactive as well as pro-thrombotic properties, promoting the activation and aggregation of nearby platelets [26]. Moreover, it has been suggested that TxA2 may have a role in mediating the vasoconstrictor response of soluble fibrin in septic conditions [27]. Nonsteroidal anti-inflammatory drugs decrease platelet adhesiveness by interfering with platelet prostaglandin synthesis, such as the TxA2 metabolite TxB2 [26], partially restoring vasopletic pulmonary regions and thus promoting an improvement in lung perfusion.

The tendency to normalization of the A-a O2 gradient couldn’t be secondary to recruitment or to changes in intrapulmonary shunt, as PEEP values (on average 10 cmH2O) were never increased during the study or were diminished, and CPAP was removed after 72 hours (Table S1 and Fig. 2). Indeed, an improvement in A-a O2 gradient could be secondary to an improvement in lung perfusion, with consequent positive effects on lung mechanics and respiratory drive, sparing patients from the harmful effects of excessive lung distension and mechanical stress [2]. It should be highlighted that participants entered the study at different timings in respect to the hospital admission. Despite a clear effect size gradient of the study therapy was not discernable, due to the natural history of the disease, it seems plausible to speculate that the maximal therapeutic advantage might be obtained in earlier disease stages. Recent evidence have linked myocardial injury and cardiovascular comorbidities with increased risk of severe disease and death [28]. In light of these data, we can not exclude that a precocious antithrombotic therapy might have a role in preventing cardiovascular complications in patients with COVID-19 pneumonia.

Currently, only one retrospective study demonstrated an advantage of anticoagulant therapy with low molecular weight heparin (LMWH) in terms of survival in patients with severe Covid-19 and signs of sepsis-induced coagulopathy [8]. Fibrinolytic agents such as tissue-type plasminogen activator have been proposed as a treatment for Covid-19 patients with coagulopathy [9]. However, we reason that an uncontrolled fibrinolysis affecting regionally inhomogeneous intra-capillary clotting might worsen blood arterialization by creating intra-parenchymal shunt when perfusion is restored in otherwise unventilated regions.

The present study has limitations. The results are influenced by a selection bias and by the limited sample size. Baseline characteristics and disease natural history varied from patient to patient, limiting the generalizability of the results. Considered the severity of the patients involved in the study, the case-control matching resulted difficult to perform. Thus the comparison might be biased by worse outcomes in the control group, which might be confounded by baseline lymphopenia, although the difference between groups was not statistically significant. However, it should be recognized that patients had a comparable mortality risk based on the severity of respiratory failure and the elevation of D-dimer. We are also aware of the multiple
progressive respiratory distress secondary to sepsis. The substantial and rapid increase in PaO2 and PAO2/FIO2 in patient #1 soon after treatment with tiro

secondary to impeding sepsis rather than a direct and isolated ef

appears disproportionate compared with the variations observed in other patients. The latter was probably secondary to a concomitant increase in cardiac output

luation of the patients

served in the present study. We underline the need for a careful eva-

sessment of the prevalent dysfunction that drives the hypoxemia.

therapeutic doses of LMWH [18]. Major bleeding events were not ob-

bleeding episodes have been reported especially in patients treated with

patients are exposed. In patients with COVID-19 without signs of CID,

therapy should be always weighted against the risk of bleeding to which

lack of nuclear medicine in our hospital, it was not possible to perform

scintigraphy. Unfortunately, due to the issues related to patients

on lung micro vasculature could have been the ventilation perfusion

V/Q mismatch and thus to monitor the e

targeted mechanistic studies are needed to ascertain the results

presented. We acknowledge that the best tool to prove the presence of

V/Q mismatch and thus to monitor the effects of antiplatelet therapy on lung micro vasculature could have been the ventilation perfusion scintigraphy. Unfortunately, due to the issues related to patients’ transport during helmet CPAP therapy, the elevated contamination risk of nuclear medicine environment and healthcare personnel, and the lack of nuclear medicine in our hospital, it was not possible to perform the test. Finally, the opportunity to introduce a triple antiplatelet therapy should be always weighted against the risk of bleeding to which patients are exposed. In patients with COVID-19 without signs of CID, bleeding episodes have been reported especially in patients treated with therapeutic doses of LMWH [18]. Major bleeding events were not observed in the present study. We underline the need for a careful evaluation of the patients’ baseline risk factors, and of an accurate assessment of the prevalent dysfunction that drives the hypoxemia.

5. Conclusions

Although preliminary, these findings, combined with available ex vivo lung pathology, should stimulate the re-evaluation of mega-
karyocyte-platelet role in the pro-thrombotic state in Covid-19 patients and suggest possible alternative treatments that may involve anti-
platelet therapy along with thrombosis prophylaxis. Still, which is the best therapeutic approach to face the thrombophilic diathesis of pa-

patients with severe Covid-19 remains unknown. Indeed, larger cohorts and randomized trials are urgently needed to answer this question.

Funding

The cost of the compassionate therapy was covered by “Fondazione Un Cuore per Milano”, a no-profit organization. Chairmen: Prof. Maurizio Viecca. Registered office: via Giannantonio Boltraffio, 7. 20159 – Milano, Italy. Tel +39 026075791. Operational headquarter: Department of Cardiology, Cardiology Unit, Ospedale Luigi Sacco, Via

Table 3

Bleed count parameters at different time-points after study drugs administration in treated patients (n = 5) and compared with matched controls. Data are expressed as means (standard deviation). Within – P(1) - and between - P(2) – group difference is reported. Statistically significant differences are in bold. For abbreviations please see Table 1 and main text.

| Blood count/ biochemistry | Group | Baseline | 24 h | 48 h | 7 d | P (1) | P (2) |
|---------------------------|-------|---------|-----|-----|-----|-------|-------|
| WBC, x10^3/L              | Treated | 10616 (3478) | 10700 (4247) | 11924 (5889) | 8570 (1727) | 0.242 | 0.685 |
| Control                   | 10454 (4589) | 6990 (2096) | 10915 (4314) | 9888 (4223) | 0.508 |       |
| Neutrophils, x10^3/L      | Treated | 8500 (3230) | 8356 (4581) | 9880 (7424) | 6094 (2100) | 0.301 | 0.869 |
| Control                   | 9176 (4681) | 6085 (2177) | 10530 (3761) | 8524 (4350) | 0.630 |       |
| Lymphocytes, x10^3/L      | Treated | 1208 (480) | 1328 (540) | 1380 (698) | 1422 (302) | 0.833 | 0.021 |
| Control                   | 730 (209) | 678 (319) | 468 (187) | 778 (525) | 0.179 | 0.377 |
| PLT, x10^3/L              | Treated | 253 (113) | 276 (130) | 305 (141) | 215 (121) | 0.147 | 0.377 |
| Control                   | 251 (130) | 237 (133) | 199 (96) | 246 (107) | 0.573 |       |
| Hb, g/L                   | Treated | 11.88 (1.4) | 11.9 (1.4) | 11.9 (5.6) | 11.5 (5.6) | 0.136 | 0.695 |
| Control                   | 12.7 (1.0) | 12.0 (1.2) | 10.8 (1.7) | 10.9 (2.0) | 0.112 |       |
| Ht, L/L                   | Treated | 35.2 (4.3) | 35.4 (4.0) | 35.5 (5.9) | 33.6 (6.5) | 0.761 | 0.785 |
| Control                   | 36 (4) | 36 (5) | 34 (7) | 31 (6) | 0.045 |       |
| D-dimer, μg/L FEU         | Treated | 3038 (995) | 5309 (5309) | 5229 (6637) | 2202 (1191) | 0.577 | 0.749 |
| Control                   | 4038 (1301) | 4562 (2348) | 5324 (5537) | 4669 (5140) | 0.678 |       |
| Fibrinogen, g/L           | Treated | 5.6 (1.3) | 5.6 (1.3) | 5.8 (1.2) | 5.7 (2.7) | 0.724 | 0.206 |
| Control                   | 6.2 (0.8) | 6.0 (1.4) | 4.3 (1.2) | 4.5 (1.7) | 0.329 |       |
| PT, s                     | Treated | 14 (1.3) | 13 (1.3) | 14 (2.5) | 13 (5.8) | 0.366 | 0.700 |
| Control                   | 14.6 (1.5) | 13.6 (1.4) | 14.4 (1.3) | 14.0 (1.2) | 0.859 |       |
| PTt, s                    | Treated | 30 (4.1) | 30 (8.6) | 33 (7.1) | 34 (8.6) | 0.179 | 0.827 |
| Control                   | 33 (5) | 31 (3) | 30 (5) | 32 (3) | 0.590 |       |
| LDH, U/L                  | Treated | 402 (211) | 447 (186) | 432 (226) | 337 (103) | 0.394 | 0.082 |
| Control                   | 591 (291) | 549 (199) | 571 (423) | 438 (247) | 0.610 |       |
| Creatinine, mg/dL         | Treated | 0.68 (0.27) | 0.72 (0.39) | 0.70 (0.35) | 0.84 (0.54) | 0.190 | 0.757 |
| Control                   | 0.84 (0.22) | 0.81 (0.26) | 0.87 (0.49) | 0.80 (0.45) | 0.625 |       |
| BUN, mg/dL                | Treated | 36 (7.6) | 30 (5.2) | 33 (10.5) | 36 (17.6) | 0.702 | 0.228 |
| Control                   | 41 (14) | 39 (18) | 48 (26) | 34 (19) | 0.650 |       |
| CRP, mg/L                 | Treated | 62 (45.5) | 55 (41.8) | 57 (54.0) | 28 (34.1) | 0.044 | 0.291 |
| Control                   | 150 (117) | 68 (87) | 71 (45) | 41 (57) | 0.380 |       |

![Fig. 2. Changes in respiratory support in treated patients and controls. Variations in the respiratory support after the initiation of study treatment (left) and in controls (right). Each line identifies a patient. Three patients from the treated group (patient #2, patient #3 and patient #5) were weaned from CPAP after three days, and patient #5 was weaned from O2 therapy after seven days. Patient #1 assessment stopped 48 hours after study protocol initiation because he was transferred to the ICU and intubated because of high PaCO2.](image-url)
G.B. Grassi 74, 20157 Milano, Italy.

Data Access, Responsibility, and Analysis

M.V and P.S. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. M.V and G.B.F. (Department of Cardiology, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy), D.R. (Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy) and (P.S. (Department of Biomedical and Clinical Sciences (DBIC), Università degli Studi di Milano, Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy) conducted and are responsible for the data analysis.

Data Sharing Statement

Individual patient data will be available, upon individual and specific request, to researchers whose proposed use of the data has been approved. Data will be made available request to: pierachille.santus@unimi.it

Data will be provided with investigator support, after approval and after signing a data access agreement. The use of individual patient data outside personal consultation will not be permitted.

Declaration of Competing Interest

Outside personal consultation will not be permitted. after signing a data access agreement. The use of individual patient data approved. Data will be made available request to: pierachille.santus@unimi.it

Individual patient data will be available, upon individual and specific request, to researchers whose proposed use of the data has been approved. Data will be made available request to: pierachille.santus@unimi.it

Data will be provided with investigator support, after approval and after signing a data access agreement. The use of individual patient data outside personal consultation will not be permitted.

Acknowledgements

M.V, G.B.F. and P.S. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Declaration of Competing Interest

Individual patient data will be available, upon individual and specific request, to researchers whose proposed use of the data has been approved. Data will be made available request to: pierachille.santus@unimi.it

Data will be provided with investigator support, after approval and after signing a data access agreement. The use of individual patient data outside personal consultation will not be permitted.

Declaration of Competing Interest

Individual patient data will be available, upon individual and specific request, to researchers whose proposed use of the data has been approved. Data will be made available request to: pierachille.santus@unimi.it

Data will be provided with investigator support, after approval and after signing a data access agreement. The use of individual patient data outside personal consultation will not be permitted.

Declaration of Competing Interest

M.V and P.S. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. M.V and G.B.F. (Department of Cardiology, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy), D.R. (Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy) and (P.S. (Department of Biomedical and Clinical Sciences (DBIC), Università degli Studi di Milano, Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy) conducted and are responsible for the data analysis.

Data Sharing Statement

Individual patient data will be available, upon individual and specific request, to researchers whose proposed use of the data has been approved. Data will be made available request to: pierachille.santus@unimi.it

Data will be provided with investigator support, after approval and after signing a data access agreement. The use of individual patient data outside personal consultation will not be permitted.

Declaration of Competing Interest

Individual patient data will be available, upon individual and specific request, to researchers whose proposed use of the data has been approved. Data will be made available request to: pierachille.santus@unimi.it

Data will be provided with investigator support, after approval and after signing a data access agreement. The use of individual patient data outside personal consultation will not be permitted.

Declaration of Competing Interest

M.V and P.S. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. M.V and G.B.F. (Department of Cardiology, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy), D.R. (Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy) and (P.S. (Department of Biomedical and Clinical Sciences (DBIC), Università degli Studi di Milano, Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy) conducted and are responsible for the data analysis.

Data Sharing Statement

Individual patient data will be available, upon individual and specific request, to researchers whose proposed use of the data has been approved. Data will be made available request to: pierachille.santus@unimi.it

Data will be provided with investigator support, after approval and after signing a data access agreement. The use of individual patient data outside personal consultation will not be permitted.

Declaration of Competing Interest

M.V and P.S. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. M.V and G.B.F. (Department of Cardiology, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy), D.R. (Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy) and (P.S. (Department of Biomedical and Clinical Sciences (DBIC), Università degli Studi di Milano, Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy) conducted and are responsible for the data analysis.

Data Sharing Statement

Individual patient data will be available, upon individual and specific request, to researchers whose proposed use of the data has been approved. Data will be made available request to: pierachille.santus@unimi.it

Data will be provided with investigator support, after approval and after signing a data access agreement. The use of individual patient data outside personal consultation will not be permitted.

Declaration of Competing Interest

M.V and P.S. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. M.V and G.B.F. (Department of Cardiology, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy), D.R. (Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy) and (P.S. (Department of Biomedical and Clinical Sciences (DBIC), Università degli Studi di Milano, Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy) conducted and are responsible for the data analysis.

Data Sharing Statement

Individual patient data will be available, upon individual and specific request, to researchers whose proposed use of the data has been approved. Data will be made available request to: pierachille.santus@unimi.it

Data will be provided with investigator support, after approval and after signing a data access agreement. The use of individual patient data outside personal consultation will not be permitted.

Declaration of Competing Interest

M.V and P.S. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. M.V and G.B.F. (Department of Cardiology, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy), D.R. (Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy) and (P.S. (Department of Biomedical and Clinical Sciences (DBIC), Università degli Studi di Milano, Division of Respiratory Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milano, Italy) conducted and are responsible for the data analysis.

Data Sharing Statement

Individual patient data will be available, upon individual and specific request, to researchers whose proposed use of the data has been approved. Data will be made available request to: pierachille.santus@unimi.it

Data will be provided with investigator support, after approval and after signing a data access agreement. The use of individual patient data outside personal consultation will not be permitted.